Drug-related Deaths

John Slinger Excerpts

Wednesday 5th November 2025 Commons Chamber

[Charlotte Nichols]

My right hon. Friend is exactly right. The clearest way to recovery is with companionship and support—there is no path to recovery without that—and I of course give credit to the organisation she mentioned that is doing such fantastic work in this space, as we were discussing earlier today.

The implications of the under-reporting of drug-related deaths are that the problem is far worse than previously thought and the decision to cut funding to services under the previous Government was based on flawed figures. The National Audit Office reported that between 2014 and 2022 there was a 40% reduction in real-terms spending on adult drug and alcohol services, so I do not think it is a coincidence that the Office for National Statistics has reported a near doubling in drug-related deaths since 2014, and that the number of deaths only rises every year.

It is clear that the problem has been made substantively worse by under-investment by the previous Government. We can all acknowledge that, but acknowledgment without reform is meaningless. Persisting with failed, punitive policies will only deepen a crisis that already ranks among Europe’s worst. Now is the time to show the difference a Labour Government can make by putting in place harm-reduction policies that will start to undo this extensive damage.

As I mentioned previously, and I will repeat again because it is important, near half of all drug-related deaths registered in 2024 were confirmed to involve an opioid. In addition, this year’s ONS report found that the number of deaths involving nitazenes—a group of highly potent synthetic opioids—almost quadrupled from the year before. This marks the beginning of a new stage in the drug-related deaths crisis. As we have seen across the Atlantic, once those synthetic opioids take hold, it becomes all the more difficult to limit their devastation.

I welcome this Government’s changes to the human medicines regulation that further expanded access to naloxone, the lifesaving opioid antidote administered in the event of an overdose. Indeed, naloxone plays a vital role in the fight against drug-related deaths. However, further change is necessary and naloxone should be available rapidly and reliably in every community pharmacy in the UK, so that it can be quickly accessed in the event of an overdose.

It is important to note that naloxone cannot be administered by the person overdosing and must instead be administered by someone else. That necessitates further education on the existence of naloxone, and how and when to use it, with people who may come into contact with people who use opioids, including frontline service workers, such as police officers and transport workers, and the loved ones of those struggling with addiction.

The period immediately after release from prison or discharge from hospital is when risk peaks. Opt-out pathways for naloxone distribution should be the norm. Take-home naloxone on release or discharge, same-day linkage to community treatment and a clear pathway for handover care are essential for people struggling with substance use disorders.

As of December 2021, the Government estimated the annual cost of illegal drug use in England to be £20 billion. Around 48% of that was attributed to drug-related crime, while harms linked to drug-related deaths and homicide accounted for a further 33%. Notably, the majority of those costs are associated with the estimated 300,000 people who use opiates and crack cocaine in England.

Dame Carol Black’s landmark 2021 review of UK drug policy found that for every for every £1 spent on treatment, £4 are saved through reduced demand on the health and justice systems. In the face of rising fatalities and a cost of living crisis, failing to scale treatment and harm-reduction measures is both morally indefensible and financially illiterate. If we want to realise that four-to-one return, we must provide long-term funding for organisations delivering services. Drug treatment services can only deliver if they are able to retain staff, train consistently and scale according to demand.

[John Slinger (Rugby) (Lab)]

I commend my hon. Friend for bringing this important debate to the House. Does she agree that organisations such as Change Grow Live, which I have visited in Rugby, are doing superb work with people as they recover after the problems that they have been facing, and that it is incumbent upon all of us to do everything we can to encourage the Government to ensure that those organisations get the funding and support they need to do that important work?

[Charlotte Nichols]

My hon. Friend is exactly right: Change Grow Live is a fantastic organisation. Multi-year funding schemes with clear outcome metrics, such as faster time for treatment, improved retention and improved naloxone coverage, will make a difference in bringing down the figures I have talked about. That is the path out of this crisis.

I recently received a letter from my hon. Friend the Minister for Policing and Crime stating she could not support overdose prevention centres because of concerns about organised crime supplying the drugs there. Overdose prevention centres are a frontline, evidence-based intervention that save lives and public money, reducing ambulance call-outs and A&E attendances, cutting public injecting and needlestick injuries, and creating a bridge into treatment. I recognise and share the Minister’s concerns about supply but, with or without such centres, people will use the same drugs, either in alleyways and stairwells or in safe hygienic settings where sharps are disposed of, and where staff can intervene and build relationships that can be the foundation for recovery from addiction.

The Scottish Affairs Committee recently published a report into problem drug use in Scotland and Glasgow’s safer drug consumption facility, and it is interesting to note the call for legislative action from the UK Government and Parliament and the fact that they seem to share my frustration with the Home Office’s ideological rather than evidence-based approach on safer drug consumption facilities.

In written correspondence to me, my hon. Friend the Minister for Policing and Crime also maintains that supplying essential safer inhalation equipment would contravene current legislation, and that the Government are unable to support such a provision or to provide a legal pathway to address this. Encouraging drug users to change their method of consuming drugs from injecting to inhaling can be an important harm reduction step, yet while supplying clean hypodermic needles is exempt under section 9A of the Misuse of Drugs Act 1971, the Government continue to support a policy of criminalisation of potential providers and users of safer inhalation equipment.